Ju Yuan Xie
Directeur/Membre du Conseil chez Konfoong Biotech International Co., Ltd.
Profil
Ju Yuan Xie currently works as a Director at Konfoong Biotech International Co., Ltd.
Postes actifs de Ju Yuan Xie
| Sociétés | Poste | Début |
|---|---|---|
Konfoong Biotech International Co., Ltd.
 Konfoong Biotech International Co., Ltd. Medical SpecialtiesHealth Technology Konfoong Biotech International Co., Ltd. is a high-tech bio-information technology enterprise based in China. The Chinese company has built numerous pathology teleconsultation platforms, including several provincial centers nationwide, and its digital pathology products have been implemented in almost 1,000 hospitals across the country. Konfoong Biotech has also been actively incorporating artificial intelligence technology to promote product innovation and has launched over 10 artificial intelligence-aided pathology diagnosis projects, such as cervical fluid-based cytology, liver pathology, kidney pathology, and breast pathology, to develop intelligent pathology-aided diagnosis systems. The company was founded in 2011 by Bing Xian Liu, who has been the CEO since then. | Directeur/Membre du Conseil | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Konfoong Biotech International Co., Ltd.
Konfoong Biotech International Co., Ltd. Medical SpecialtiesHealth Technology Konfoong Biotech International Co., Ltd. is a high-tech bio-information technology enterprise based in China. The Chinese company has built numerous pathology teleconsultation platforms, including several provincial centers nationwide, and its digital pathology products have been implemented in almost 1,000 hospitals across the country. Konfoong Biotech has also been actively incorporating artificial intelligence technology to promote product innovation and has launched over 10 artificial intelligence-aided pathology diagnosis projects, such as cervical fluid-based cytology, liver pathology, kidney pathology, and breast pathology, to develop intelligent pathology-aided diagnosis systems. The company was founded in 2011 by Bing Xian Liu, who has been the CEO since then. | Health Technology |
